Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advanced renal cell carcinoma.

M I Milowsky1, D M Nanus

  • 1Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, 525 East 68th Street, B-1519, New York, NY 10021, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma.

ESMO open·2026
Same author

Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Integrative radiomics expression predicts molecular subtypes of primary clear cell renal cell carcinoma.

Clinical radiology·2018
Same author

Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.

World journal of urology·2016
Same author

Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.

Clinical pharmacology and therapeutics·2015

Advanced renal cell carcinoma (RCC) is difficult to treat, with limited success from current therapies. New treatments are urgently needed to improve outcomes for patients with this resistant cancer.

Area of Science:

  • Oncology
  • Urology
  • Nephrology

Background:

  • Advanced renal cell carcinoma (RCC) presents significant treatment challenges due to high resistance to systemic therapies.
  • Current treatment modalities including chemotherapy, immunotherapy, and radiation therapy have shown limited efficacy.
  • Interleukin-2 (IL-2) and interferon-alfa (IFN alfa)-based therapies offer low but reproducible response rates (10-20%) with minimal durable responses (<5%).

Purpose of the Study:

  • To review the current treatment landscape for advanced renal cell carcinoma.
  • To highlight the limitations of existing therapies and the need for novel treatment strategies.
  • To discuss emerging therapeutic approaches and the ongoing search for more effective agents.

Main Methods:

  • Review of existing literature on advanced renal cell carcinoma treatment.

Related Experiment Videos

  • Analysis of response rates and survival advantages associated with various treatment modalities.
  • Exploration of novel therapeutic strategies currently under investigation.

    • Main Results:

    • Systemic therapies for advanced RCC have historically yielded poor and inconsistent outcomes.
    • Surgery (nephrectomy) is a viable option for patients with metastatic or resectable disease prior to systemic therapy.
    • While IL-2 and IFN alfa show modest, reproducible responses, their durable efficacy is limited.
    • Recent studies suggest a marginal survival advantage with IFN-based therapy.
    • Emerging strategies like vaccines and allogeneic bone marrow transplant show early promise.

    Conclusions:

    • Advanced RCC remains a highly resistant malignancy requiring innovative treatment approaches.
    • The identification and development of novel agents with superior antitumor activity are critical priorities.
    • While established therapies offer limited benefits, ongoing research into new modalities holds potential for improved patient outcomes.